0001787306-24-000085.txt : 20240531
0001787306-24-000085.hdr.sgml : 20240531
20240531165040
ACCESSION NUMBER: 0001787306-24-000085
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240529
FILED AS OF DATE: 20240531
DATE AS OF CHANGE: 20240531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burnett Patrick
CENTRAL INDEX KEY: 0001741987
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39186
FILM NUMBER: 241010536
MAIL ADDRESS:
STREET 1: C/O VERRICA PHARMACEUTICALS INC.
STREET 2: 10 NORTH HIGH STREET, SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001787306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812974255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-418-5006
MAIL ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: Arcutis, Inc.
DATE OF NAME CHANGE: 20190905
4
1
wk-form4_1717188632.xml
FORM 4
X0508
4
2024-05-29
0
0001787306
Arcutis Biotherapeutics, Inc.
ARQT
0001741987
Burnett Patrick
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD SUITE 300
WESTLAKE VILLAGE
CA
91361
0
1
0
0
See Remarks
0
Common Stock
2024-05-29
4
S
0
49952
8.7161
D
209793
D
Common Stock
2024-05-30
4
M
0
23000
0
A
232793
D
Common Stock
2024-05-30
4
S
0
23000
8.753
D
209793
D
Stock Option (right to buy)
3.64
2024-05-30
4
M
0
23000
0
D
2034-01-12
Common Stock
23000
253000
D
The transaction was executed in multiple trades in prices ranging from $8.50 to $8.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $8.70 to $8.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Reporting Person's title: SVP Chief Medical Officer
/s/ David Topper, as Attorney-in-Fact for Patrick Burnett
2024-05-31